NRAS and colorectal carcinoma: In the Ras signaling pathway, aside from the dominant KRAS alterations (5/19), we had a patient with NRAS alteration (1/19) and this gene was previously reported to be altered in about five to eight percent of CRC patients (Forbes et al., 2015).